Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP).
Department of Dermatology, Duke University Medical Center, Durham, NC 27710, USA.
Arash
A
Ronaghy
Department of Dermatology, Duke University Medical Center, Durham, NC 27710, USA.
Robert D
RD
Streilein
Department of Dermatology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: Russell.Hall@duke.edu.
Russell P
RP
Hall
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000737:chemistry*; D001324:Autoantigens / Q000737:chemistry*; D016022:Case-Control Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000737:chemistry; D024041:Non-Fibrillar Collagens / Q000737:chemistry*; D010391:Pemphigoid, Bullous / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D017434:Protein Structure, Tertiary; D000069283:Rituximab; D000097805:Collagen Type XVII
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D024041:Non-Fibrillar Collagens; D000069283:Rituximab; D000097805:Collagen Type XVII
Auto-antibodies: IgG subclass; Bullous pemphigoid; Rituximab